The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

The article discusses the Acute Leukemia French Association (ALFA)-0701 study which analyzes the positive impact of the level of blast CD33 expression to gemtuzumab ozogamicin (GO) in patients with acute myeloid leukemia. The in vitro result which shows the clear relationship between CD33 expression and GO efficacy and the evaluation of CD33 expression as a continuous covariable and highest response rates were reported for patients with CD33 expression in phase 2 study are mentioned.